Integral Health Asset Management LLC Invests $5.66 Million in Apellis Pharmaceuticals, Inc. $APLS

Integral Health Asset Management LLC purchased a new stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) during the third quarter, Holdings Channel reports. The firm purchased 250,000 shares of the company’s stock, valued at approximately $5,658,000.

Other hedge funds also recently bought and sold shares of the company. Jones Financial Companies Lllp raised its stake in shares of Apellis Pharmaceuticals by 206.8% during the third quarter. Jones Financial Companies Lllp now owns 2,037 shares of the company’s stock worth $46,000 after acquiring an additional 1,373 shares in the last quarter. Osaic Holdings Inc. boosted its stake in shares of Apellis Pharmaceuticals by 141.2% in the 2nd quarter. Osaic Holdings Inc. now owns 2,682 shares of the company’s stock valued at $47,000 after purchasing an additional 1,570 shares in the last quarter. Quantbot Technologies LP bought a new position in shares of Apellis Pharmaceuticals during the third quarter valued at about $64,000. EverSource Wealth Advisors LLC increased its holdings in shares of Apellis Pharmaceuticals by 338.5% in the second quarter. EverSource Wealth Advisors LLC now owns 5,429 shares of the company’s stock worth $94,000 after buying an additional 4,191 shares during the period. Finally, Headlands Technologies LLC increased its holdings in shares of Apellis Pharmaceuticals by 748.8% in the second quarter. Headlands Technologies LLC now owns 6,892 shares of the company’s stock worth $119,000 after buying an additional 6,080 shares during the period. Institutional investors own 96.29% of the company’s stock.

Insider Transactions at Apellis Pharmaceuticals

In other news, General Counsel David O. Watson sold 7,832 shares of the stock in a transaction that occurred on Thursday, January 22nd. The shares were sold at an average price of $21.77, for a total transaction of $170,502.64. Following the sale, the general counsel owned 88,531 shares in the company, valued at $1,927,319.87. This represents a 8.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Cedric Francois sold 27,192 shares of the firm’s stock in a transaction that occurred on Thursday, January 22nd. The shares were sold at an average price of $21.77, for a total transaction of $591,969.84. Following the sale, the chief executive officer directly owned 286,045 shares of the company’s stock, valued at $6,227,199.65. This trade represents a 8.68% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 120,537 shares of company stock valued at $2,608,532. 6.50% of the stock is currently owned by insiders.

Apellis Pharmaceuticals Stock Up 3.0%

Shares of Apellis Pharmaceuticals stock opened at $18.94 on Friday. Apellis Pharmaceuticals, Inc. has a 1 year low of $16.10 and a 1 year high of $30.48. The firm has a market cap of $2.42 billion, a price-to-earnings ratio of 145.70 and a beta of 0.26. The company has a 50-day moving average of $21.90 and a 200 day moving average of $23.29. The company has a debt-to-equity ratio of 0.98, a current ratio of 3.14 and a quick ratio of 2.70.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its earnings results on Tuesday, February 24th. The company reported $0.47 EPS for the quarter, topping the consensus estimate of ($0.39) by $0.86. Apellis Pharmaceuticals had a return on equity of 8.20% and a net margin of 2.23%.The business had revenue of $199.91 million for the quarter, compared to the consensus estimate of $199.28 million. During the same period in the previous year, the company posted ($0.29) earnings per share. The company’s revenue for the quarter was down 5.9% compared to the same quarter last year. As a group, sell-side analysts anticipate that Apellis Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Analyst Ratings Changes

APLS has been the topic of several recent analyst reports. Barclays started coverage on shares of Apellis Pharmaceuticals in a report on Wednesday, January 28th. They issued an “equal weight” rating and a $24.00 target price on the stock. Roth Mkm assumed coverage on Apellis Pharmaceuticals in a research note on Friday. They issued a “buy” rating and a $31.00 target price on the stock. Wells Fargo & Company reduced their price target on Apellis Pharmaceuticals from $29.00 to $26.00 and set an “overweight” rating on the stock in a report on Tuesday, January 20th. Cantor Fitzgerald dropped their price target on Apellis Pharmaceuticals from $39.00 to $35.00 and set an “overweight” rating for the company in a research note on Tuesday, January 13th. Finally, Wall Street Zen cut shares of Apellis Pharmaceuticals from a “buy” rating to a “sell” rating in a report on Saturday, February 28th. Thirteen equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $32.63.

Apellis Pharmaceuticals Profile

Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company’s research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.

The company’s lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.